| Literature DB >> 33110472 |
María E López-Navarro1, Mariana Jarquín-Martínez1, Luis A Sánchez-Labastida1, Daniel Ramírez-Rosales2, Marycarmen Godínez-Victoria1, Laura Itzel Quintas-Granados3, José Guadalupe Trujillo-Ferrara1.
Abstract
N-aryl maleimides can undergo a 1,4-Michael-type addition reaction with reduced glutathione (GSH), leading to a decreased concentration of GSH and an increased concentration of free radicals (FRs) in cells. GSH is a critical scavenging molecule responsible for protecting cells from oxidation and for maintaining redox homeostasis. N-aryl maleimides disturb redox homeostasis in cells because they scavenge thiol-containing molecules, especially GSH. This study aimed at measuring the concentrations of GSH and FRs by electronic paramagnetic resonance (EPR), in the brain and liver tissue of male Wistar rats (ex vivo) at different ages and after treatment with 3,5-dimaleimylbenzoic acid (3,5-DMB). Our results showed a relationship between age and the concentrations of GSH and FRs in cells. In young rats, the concentration of GSH was higher than in old rats, while the concentration of FRs was higher in adult rats than in young rats, suggesting an inverse relationship between GSH and FRs. On the other hand, the reaction of 3,5-DMB (an electrophilic maleimide) with cellular GSH increased the FR content. The results of this study contribute to the awareness that the process of aging implies not only a loss of tissue function but also essential changes in the molecular contents of cells, especially the concentrations of FRs and GSH.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33110472 PMCID: PMC7578726 DOI: 10.1155/2020/3970860
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Scheme 1Synthesis of 3,5-dimaleimylbenzoic acid (3,5-DMB). Stage 1: 3,5-diaminobenzoic acid was reacted with maleic anhydride. Stage 2: cyclization of the precursor maleamide was achieved through dehydration with anhydrous sodium acetate to provide 3,5-DMB.
Theoretical global and local descriptors for 3,5-DMB, N-acetyl cysteine, cysteine, and GSH.
| Compound | ||||||||
|---|---|---|---|---|---|---|---|---|
| 3,5-DMB | Global descriptors | |||||||
|
|
|
|
|
|
|
|
| |
| -5.1062 | -6.8024 | -3.4100 | 3.0180 | 0.1657 | 3.4198 | 6.0687 | 1.5254 | |
| Local softness | ||||||||
| C=C (C3–C4) | 0.0066 | |||||||
| C=O | 0.0046 | |||||||
|
| ||||||||
| N-acetyl cysteine1 | Global descriptors | |||||||
|
|
|
|
|
|
|
|
| |
| -3.8521 | -6.2548 | -1.4493 | 4.8055 | 0.1040 | 1.5439 | 4.0706 | 0.2186 | |
| Local softness | ||||||||
| SH | 0.0452 | |||||||
|
| ||||||||
| Cysteine | Global descriptors | |||||||
|
|
|
|
|
|
|
|
| |
| -3.3075 | -6.0074 | -0.6076 | 5.3998 | 0.0926 | 1.0129 | 3.3417 | 0.0342 | |
| Local softness | ||||||||
| SH | 0.0318 | |||||||
|
| ||||||||
| GSH | Global descriptors | |||||||
|
|
|
|
|
|
|
|
| |
| -3.6495 | -5.8221 | -1.4286 | 4.3936 | 0.1138 | 1.4957 | 3.8576 | 0.2322 | |
| Local softness | ||||||||
| SH | 0.0246 | |||||||
3,5-DMB: 3,5-dimaleimylbenzoic acid, GSH: reduced Glutathione, μ: chemical potential, μ-: donating potential, μ+: acceptor potential, η: global hardness value, S: global softness, ω: Electrophilicity index, ω−: electron-donating power, ω+: electron-accepting power, eV: electronvolt. 1Global local indexes of reactivity for N-acetyl cysteine were taken from published data [8, 13].
Figure 1Proposed reaction mechanism for 3,5-dimaleimylbenzoic (3,5-DMB) acid with glutathione (GSH). The α,β-unsaturated carbonyl structure in 3,5-DMB acts as an electrophile, carrying out a 1,4-Michael-type reaction with the sulfur atom (S) from the thiol group of the cysteine residue in GSH (IUPAC-based numerical assignment). The β-carbon atom (C3) is shown as the preferred site of attack due to its positive polarization, whereas GSH acts as a Michael acceptor because of its high reactivity toward soft electrophiles, such as α,β-unsaturated compounds.
Quantification of free radicals and GSH in brain and liver tissue extracted from Wistar rats at various ages and treated with 3,5-DMB several times.
| Age (months) | Tissue (1 g) | Relative number of FRs1 | GSH content (mol/g)2 |
|---|---|---|---|
| 2 | Brain | 4.95 × 104 ± 1.36 × 103 | 2.46 × 10−5 ± 1.30 × 10−7 |
| Liver | 5.10 × 104 ± 0.88 × 103 | 4.76 × 10−5 ± 1.12 × 10−6 | |
| 3 | Brain | 6.24 × 104 ± 0.94 × 103 | 2.33 × 10−5 ± 1.86 × 10−7 |
| Liver | 14.93 × 104 ± 2.59 × 103 | 4.32 × 10−5 ± 1.04 × 10−7 | |
| 5 | Brain | 9.71 × 104 ± 1.08 × 103 | 2.31 × 10−5 ± 8.30 × 10−8 |
| Liver | 18.75 × 104 ± 4.10 × 103 | 4.15 × 10−5 ± 2.51 × 10−7 | |
| 7 | Brain | 12.92 × 104 ± 2.78 × 103 | 2.22 × 10−5 ± 4.81 × 10−7 |
| Liver | 36.90 × 104 ± 2.33 × 103 | 4.03 × 10−5 ± 4.94 × 10−7 | |
| 8 | Brain | 23.71 × 104 ± 13.90 × 103 | 1.99 × 10−5 ± 1.36 × 10−6 |
| Liver | 45.87 × 104 ± 2.82 × 103 | 3.81 × 10−5 ± 1.00 × 10−6 | |
| 12 | Brain | 29.10 × 104 ± 4.37 × 103 | 1.93 × 10−5 ± 7.14 × 10−7 |
| Liver | 57.77 × 104 ± 3.99 × 103 | 3.59 × 10−5 ± 5.30 × 10−7 | |
| 18 | Brain | 35.48 × 104 ± 5.59 × 103 | 1.65 × 10−5 ± 7.40 × 10−8 |
| Liver | 122.34 × 104 ± 14.75 × 103 | 2.60 × 10−5 ± 1.33 × 10−6 | |
| Posttreatment time (h) | |||
| 0 | Brain | 32.88 × 104 ± 6.51 × 103 | 1.73 × 10−5 ± 1.36 × 10−7 |
| Liver | 62.67 × 104 ± 39.07 × 103 | 3.47 × 10−5 ± 1.95 × 10−6 | |
| 1 | Brain | 15.26 × 104 ± 11.84 × 103 | 2.35 × 10−5 ± 4.35 × 10−7 |
| Liver | 46.68 × 104 ± 7.44 × 103 | 3.53 × 10−5 ± 1.03 × 10−6 | |
| 2 | Brain | 28.42 × 104 ± 0.85 × 103 | 1.77 × 10−5 ± 6.17 × 10−7 |
| Liver | 72.66 × 104 ± 38.21 × 103 | 1.94 × 10−5 ± 7.31 × 10−7 | |
| 4 | Brain | 26.04 × 104 ± 1.32 × 103 | 1.97 × 10−5 ± 5.26 × 10−7 |
| Liver | 59.50 × 104 ± 6.71 × 103 | 2.98 × 10−5 ± 1.23 × 10−6 | |
| 6 | Brain | 60.57 × 104 ± 23.13 × 103 | 1.62 × 10−5 ± 8.95 × 10−7 |
| Liver | 72.05 × 104 ± 13.47 × 103 | 1.91 × 10−5 ± 1.37 × 10−6 | |
| 8 | Brain | 49.90 × 104 ± 15.28 × 103 | 1.42 × 10−5 ± 9.51 × 10−7 |
| Liver | 83.25 × 104 ± 12.16 × 103 | 2.01 × 10−5 ± 1.98 × 10−6 | |
| 12 | Brain | 47.00 × 104 ± 10.20 × 103 | 1.12 × 10−5 ± 9.59 × 10−7 |
| Liver | 81.68 × 104 ± 22.13 × 103 | 2.29 × 10−5 ± 2.26 × 10−6 | |
| 16 | Brain | 45.73 × 104 ± 14.99 × 103 | 1.40 × 10−5 ± 2.84 × 10−7 |
| Liver | 85.94 × 104 ± 49.69 × 103 | 2.09 × 10−5 ± 1.01 × 10−6 | |
1Data from EPR analysis performed on tissue from three rats (mean ± standard deviation). 2Data were calculated from tissue from three rats and are expressed as the mean ± standard deviation.
Figure 2Effect of age on the levels of GSH and FRs. Male Wistar rats were used to obtain 1 g of brain (-•-) and liver (-∎-) tissue at 2-18 months of age (n = 3 for each age and tissue) to quantify the relative concentrations of FRs (a) and GSH (b). Circles and squares represent the mean ± standard deviation of three values from each sample extracted at a given measurement time. Experimental data were adjusted to a linear regression (solid lines). The statistical value (r2) is denoted in each polynomial regression plot. The solid lines indicate the experimental values for the liver (-∎-) tissue, and the dashed indicate the experimental values for the brain (-•-) tissue. Overall, the analysis indicates that with aging, the concentration of GSH decreases, and the FR content increases in both tissues (c).
Figure 3Effect of 3,5-DMB on the levels of GSH and FRs at 16 hours posttreatment in male Wistar rats. Evaluations were performed at 1, 2, 4, 6, 8, 12, and 16 h posttreatment with 3,5-DMB (n = 3). The relative number of FRs (-∎-) and concentration of GSH (-•-) were determined in 1 g of brain tissue (a) and liver tissue (b). The standard deviation is shown. Linear regression plots for FRs (gray solid line) or GSH (black dashed line) in untreated samples from brain or liver tissue (Figure 2) are included for comparison.